Novartis stock holds firm on earnings and pipeline strength
Published on 08/09/2026 at 14:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock (Novartis AG, ISIN CH0012005267) is anchored by a CHF 10.35 billion second-quarter revenue base and first-half 2026 diluted earnings per share of $3.12, up 26% from the same period a year earlier. The company also reiterated 2026 guidance for low-teens sales growth and core operating income growth in the high teens, according to its first-half 2026 report.
CHF 10.35 billion in Q2
Revenue reached CHF 10.35 billion in the second quarter of 2026, while core operating income came in at CHF 4.36 billion for the quarter. That combination matters because Novartis paired the sales base with a 42.2% core operating margin in Q2 2026, showing that profit conversion remained high even after a large revenue base.
First-half 2026 revenue totaled $27.3 billion, and diluted earnings per share rose to $3.12 from $2.48 in the first half of 2025, a 26% increase. The comparison is the key point for investors: the company is still turning growth into higher per-share earnings, not just larger top-line numbers.
Low-teens sales growth
Novartis kept its 2026 sales outlook at low-teens growth and its core operating income outlook at high-teens growth. That guidance frame is more useful than a narrative description because it sets a clear hurdle for the second half of 2026 and leaves little room for ambiguity about the pace required to hold the current earnings trend.
The first-half report also showed core free cash flow of $7.5 billion, which gives the company room to support development spending and shareholder returns. In the same period, net cash from operating activities reached $8.6 billion, a figure that helps explain why the balance between growth and cash generation remains central to the stock.
First-half 2026 numbers and guidance
Novartis outlined the revenue, earnings, cash flow and guidance details in its latest half-year report, which gives the current valuation debate a concrete operating base.
Cash flow matters
Core free cash flow of $7.5 billion in the first half of 2026 and operating cash flow of $8.6 billion point to a business that is still financing its own pipeline and capital returns. For Novartis stock, that cash profile is the more durable metric than any single quarter’s headline revenue.
The first-half 2026 margin structure also matters because it shows how much of the sales base is converting into profit. A 42.2% Q2 core operating margin and 26% first-half EPS growth are evidence that the earnings engine is still working even as the company remains dependent on execution across the rest of 2026.
Cosentyx remains important
Cosentyx remains one of Novartis’ key medicines, and the product family still carries material weight in the group’s portfolio. In a market that rewards visible cash generation, large brands such as Cosentyx help support the company’s ability to keep revenue and earnings growth aligned.
The portfolio point matters because Novartis is not relying on a single launch story. The group’s first-half 2026 results show a broader operating model with a multi-product base, which is more relevant to valuation than any short-lived headline around one medicine.
Trading around CHF 100
Novartis stock trades on the SIX Swiss Exchange under the ticker SIX: NOVN. As a market reference point, the shares were last quoted around CHF 100.00, a level that investors can weigh against the company’s first-half 2026 revenue of CHF 21.12 billion, diluted EPS of $3.12, and core free cash flow of $7.5 billion.
The stock closes the day with a clean operating backdrop: low-teens sales growth guidance, high-teens core operating income growth guidance, and a 26% rise in first-half diluted EPS. That combination makes the next reporting step more important than broad market chatter.
Novartis AG stock data
Novartis AG
- Company: Novartis AG
- ISIN: CH0012005267
- Ticker: SIX: NOVN
- Trading venue: SIX Swiss Exchange
- Price (as of 9 August 2026, 12:00 UTC): CHF 100.00
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: SMI
